Functional status of multiple sclerosis patients during interferon therapy

被引：0

作者：

Pasic, MB ^{[1
]}

Trkanjec, Z ^{[1
]}

Lisak, M ^{[1
]}

Demarin, V ^{[1
]}

机构：

[1] Univ Zagreb, Sestre Milosrdnice Hosp, Dept Neurol, Zagreb 41000, Croatia

来源：

PROCEEDINGS OF THE 7TH CONGRESS OF THE EUROPEAN SOCIETY FOR CLINICAL NEUROPHARMACOLOGY | 2004年

关键词：

multiple sclerosis; beta interferon; therapy; functional status;

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Twenty patients (11 females and 9 males) with remitting relapsing-multiple sclerosis (RRMS) were treated with beta interferon at University Department of Neurology Sestre milosrdnice University Hospital. 13 patients are treated with interferon beta la (6 MIU 3 time weekly, subcutaneously), and 7 with interferon beta lb (9,6 MIU every other day, intramuscular). The Expanded Disaility Status Scale (EDSS) was recorded before interferon therapy and six months after interferon therapy initiation. The average EDSS score was slightly smaller after six months of interferon therapy in both groups, but the difference was not statistically significant (p=0.17 in interferon beta la group, p=0.36 in interferon beta lb group). Results in this small groups of patients favor interferon therapy in MS patients. Further follow-up are required to get additional information about functional status of MS patients during interferon therapy after longer period of time.

引用

页码：199 / 203

页数：5

共 11 条

[1] Interferon β-1a for early multiple sclerosis:: CHAMPS trial subgroup analyses [J].

Beck, RW ;

Chandler, DL ;

Cole, SR ;

Simon, JH ;

Jacobs, LD ;

Kinkel, RP ;

Selhorst, JB ;

Rose, JW ;

Cooper, JA ;

Rice, G ;

Murray, TJ ;

Sandrock, AW .

ANNALS OF NEUROLOGY, 2002, 51 (04) :481-490

[2] INTERFERON BETA-1B IS EFFECTIVE IN RELAPSING-REMITTING MULTIPLE-SCLEROSIS - CLINICAL-RESULTS OF A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].

DUQUETTE, P ;

GIRARD, M ;

DESPAULT, L ;

DUBOIS, R ;

KNOBLER, RL ;

LUBLIN, FD ;

KELLEY, L ;

FRANCIS, GS ;

LAPIERRE, Y ;

ANTEL, J ;

FREEDMAN, M ;

HUM, S ;

GREENSTEIN, JI ;

MISHRA, B ;

MULDOON, J ;

WHITAKER, JN ;

EVANS, BK ;

LAYTON, B ;

SIBLEY, WA ;

LAGUNA, J ;

KRIKAWA, J ;

PATY, DW ;

OGER, JJ ;

KASTRUKOFF, LF ;

MOORE, GRW ;

HASHIMOTO, SA ;

MORRISON, W ;

NELSON, J ;

GOODIN, DS ;

MASSA, SM ;

GUTTERIDGE, E ;

ARNASON, BGW ;

NORONHA, A ;

REDER, AT ;

MARTIA, R ;

EBERS, GC ;

RICE, GPA ;

LESAUX, J ;

JOHNSON, KP ;

PANITCH, HS ;

BEVER, CT ;

CONWAY, K ;

WALLENBERG, JC ;

BEDELL, L ;

VANDENNOORT, S ;

WEINSHENKER, B ;

WEISS, W ;

REINGOLD, S ;

PACHNER, A ;

TAYLOR, W .

NEUROLOGY, 1993, 43 (04) :655-661

[3] Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN) [J].

Durelli, L ;

Verdun, E ;

Barbero, P ;

Bergui, M ;

Versino, E ;

Ghezzi, A ;

Montanari, E ;

Zaffaroni, M .

LANCET, 2002, 359 (9316) :1453-1460

[4] Interferons in relapsing remitting multiple sclerosis: a systematic review [J].

Filippini, G ;

Munari, L ;

Incorvaia, B ;

Ebers, GC ;

Polman, C ;

D'Amico, R ;

Rice, GPA .

LANCET, 2003, 361 (9357) :545-552

[5] The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis - Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology [J].

Goodin, DS ;

Arnason, BG ;

Coyle, PK ;

Frohman, EM ;

Paty, DW .

NEUROLOGY, 2003, 61 (10) :1332-1338

[6]

*IFN BETA MULT SCL, 1993, NEUROLOGY, V43, P661

[7] Intramuscular interferon beta-1 alpha for disease progression in relapsing multiple sclerosis [J].

Jacobs, LD ;

Cookfair, DL ;

Rudick, RA ;

Herndon, RM ;

Richert, JR ;

Salazar, AM ;

Fischer, JS ;

Goodkin, DE ;

Granger, CV ;

Simon, JH ;

Alam, JJ ;

Bartoszak, DM ;

Bourdette, DN ;

Braiman, J ;

Brownscheidle, CM ;

Coats, ME ;

Cohan, SL ;

Dougherty, DS ;

Kinkel, RP ;

Mass, MK ;

Munschauer, FE ;

Priore, RL ;

Pullicino, PM ;

Scherokman, BJ ;

WeinstockGuttman, B ;

Whitman, RH ;

Baird, WC ;

Fillmore, M ;

Bona, LM ;

ColonRuiz, ME ;

Nadine, BS ;

Donovan, A ;

Bennett, S ;

Kieffer, YM ;

Umhauer, MA ;

Miller, CE ;

Kilic, AK ;

Sargent, EL ;

Schachter, M ;

Shucard, DW ;

Weider, V ;

Catalano, BA ;

Cervi, JM ;

Czekay, C ;

Farrell, JL ;

Filippini, JS ;

Matyas, RC ;

Michienzi, KE ;

Ito, M ;

OMalley, JA .

ANNALS OF NEUROLOGY, 1996, 39 (03) :285-294

[8] Natural history and clinical outcome measures for multiple sclerosis studies. Why at the present time does EDSS scale remain a preferred outcome measure to evaluate disease evolution? [J].

Kurtzke, JF .

NEUROLOGICAL SCIENCES, 2000, 21 (06) :339-341

[9]

La Mantia L, 2002, COCHRANE DB SYST REV

[10] Prevention of autoimmune attack and disease progression in multiple sclerosis: current therapies and future prospects [J].

Pender, MP ;

Wolfe, NP .

INTERNAL MEDICINE JOURNAL, 2002, 32 (11) :554-563

← 1 2 →